Comparison · NCT02689219-sae
CD30 Negative/Unknown vs CD30 Positive: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CD30 Negative/Unknown vs CD30 Positive: serious adverse events. Trial comparisons, record NCT02689219-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02689219-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.182 | 0.0514 | 0.477 | wilson | |
| Risk in group 2 | 0.429 | 0.158 | 0.75 | wilson | |
| Risk difference, group 1 minus group 2 | -0.247 | -0.593 | 0.154 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.424 | 0.093 | 1.94 | log | |
| Odds ratio, group 1 over group 2 | 0.296 | 0.0348 | 2.52 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on CD30 Negative/Unknown than on CD30 Positive | 4.05 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CD30 Negative/Unknown | Brentuximab Vedotin 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Negative/Unknown cohort. | 2 | 11 | EG000 |
| Group 2 | CD30 Positive | Brentuximab Vedotin 1.8 mg/ kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Positive cohort. | 3 | 7 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 1 year
Source ClinicalTrials.gov
Trial
- Title
- Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
- NCT number
- NCT02689219
- Phases
- PHASE2
- Conditions
- Germ Cell Tumors, Testis Cancer, Testicular Cancer, Embryonal Carcinoma, Nonseminomatous Germ Cell Tumor
- Interventions
- Brentuximab Vedotin
- Lead sponsor
- Nabil Adra
- Results first posted
- 2019-11-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02689219?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02689219-sae